Ganaxolone Significantly Reduces Major Motor Seizures Associated With CDKL5 Deficiency Disorder: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study (Marigold Study)
Pharmacokinetic-Pharmacodynamic Analysis of Oral Ganaxolone in Patients with CDKL5 Deficiency Disorder: Results From the Marigold Study
Intravenous Ganaxolone for the Treatment of Refractory Status Epilepticus: Results From an Open-Label, Dose-Finding, Phase 2 Study
IV Ganaxolone in Pediatric Super Refractory Status Epilepticus: A Single Patient Case Study
Ganaxolone Mechanism of Action and Pharmacology
Effect of Ganaxolone on Seizure Frequency Across Subpopulations of Patients With CDKL5 Deficiency Disorder: Subgroup Analyses of the Marigold Study
Status Epilepticus: Inpatient Burden of Illness and Association with Disease Severity
Treatment of Super Refractory Status Epilepticus Using Intravenous Ganaxolone in a Patient with Lennox-Gastaut Syndrome and Angelman Syndrome
A Double-Blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intravenous Ganaxolone in Status Epilepticus (RAISE)
Extended Duration Safety and Efficacy of Ganaxolone for the treatment of CDKL5 Deficiency Disorder: Preliminary Open-Label Extension Analysis (Marigold Study)
Intravenous Ganaxolone Achieves Rapid and Does-Dependent Sustained Improvement in EEG Seizure Burden in Patients with Refractory with Refractory Status Epilepticus (marinuspharma.com)
Pharmacokinetic and Pharmacodynamic (PK/PD) Relationship of Intravenous Ganaxolone in Refractory Status Epilepticus
Population Pharmacokinetic/Pharmacodynamic Modeling of the Electroencephalographic Effects of Ganaxolone in Healthy Subjects
Ganaxolone in CDKL5 Deficiency Disorder: Open-Label Phase 2a Results and Ongoing Pivotal Phase 3 Study Design
Long-term, Durable Seizure Frequency Reduction in Children with CDKL5 Deficiency Disorder (CDD) Treated with Ganaxolone